JP2023539370A - 有核細胞を使用してタンパク質に対するｈｌａ非依存的な免疫応答を刺激する方法 - Google Patents

有核細胞を使用してタンパク質に対するｈｌａ非依存的な免疫応答を刺激する方法 Download PDF

Info

Publication number
JP2023539370A
JP2023539370A JP2023514418A JP2023514418A JP2023539370A JP 2023539370 A JP2023539370 A JP 2023539370A JP 2023514418 A JP2023514418 A JP 2023514418A JP 2023514418 A JP2023514418 A JP 2023514418A JP 2023539370 A JP2023539370 A JP 2023539370A
Authority
JP
Japan
Prior art keywords
protein
cell
cells
nucleated
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023514418A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022051437A5 (https=
JP2023539370A5 (https=
Inventor
エムラ イルケル オザイ，
マイケル マローニー，
スコット ラフヘッド，
ハワード バーンスタイン，
キャサリン ザイドル，
メリッサ ミント，
アーモン アール． シャレイ，
Original Assignee
スクイーズ バイオテクノロジーズ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スクイーズ バイオテクノロジーズ カンパニー filed Critical スクイーズ バイオテクノロジーズ カンパニー
Publication of JP2023539370A publication Critical patent/JP2023539370A/ja
Publication of JPWO2022051437A5 publication Critical patent/JPWO2022051437A5/ja
Publication of JP2023539370A5 publication Critical patent/JP2023539370A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2023514418A 2020-09-02 2021-09-01 有核細胞を使用してタンパク質に対するｈｌａ非依存的な免疫応答を刺激する方法 Pending JP2023539370A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063073910P 2020-09-02 2020-09-02
US63/073,910 2020-09-02
US202163147473P 2021-02-09 2021-02-09
US63/147,473 2021-02-09
PCT/US2021/048771 WO2022051437A2 (en) 2020-09-02 2021-09-01 Methods to stimulate hla-agnostic immune responses to proteins using nucleated cells

Publications (3)

Publication Number Publication Date
JP2023539370A true JP2023539370A (ja) 2023-09-13
JPWO2022051437A5 JPWO2022051437A5 (https=) 2024-09-10
JP2023539370A5 JP2023539370A5 (https=) 2024-09-10

Family

ID=78212608

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023514418A Pending JP2023539370A (ja) 2020-09-02 2021-09-01 有核細胞を使用してタンパク質に対するｈｌａ非依存的な免疫応答を刺激する方法

Country Status (7)

Country Link
US (1) US20230263879A1 (https=)
EP (1) EP4208192A2 (https=)
JP (1) JP2023539370A (https=)
KR (1) KR20230079066A (https=)
CN (1) CN116406283A (https=)
TW (1) TW202227125A (https=)
WO (1) WO2022051437A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202241466A (zh) * 2020-12-29 2022-11-01 美商Ｓｑｚ生物科技公司 以經修飾ｐｂｍｃ治療癌症之方法
JP2024536840A (ja) * 2021-09-26 2024-10-08 ウーシー バイオロジクス アイルランド リミテッド Ｉｌ－２バリアント及びその融合タンパク質
WO2025140126A1 (en) * 2023-12-25 2025-07-03 Everest Medicines (China) Co., Ltd. Therapeutic ly6k mrna vaccine for cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017533702A (ja) * 2014-10-31 2017-11-16 マサチューセッツ インスティテュート オブ テクノロジー 生体分子の免疫細胞への送達
WO2019178005A2 (en) * 2018-03-12 2019-09-19 Sqz Biotechnologies Company Methods for treating hpv-associated diseases
WO2020112493A1 (en) * 2018-11-29 2020-06-04 Board Of Regents, The University Of Texas System Methods for ex vivo expansion of natural killer cells and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3131701A1 (en) * 2019-02-28 2020-09-03 Sqz Biotechnologies Company Delivery of biomolecules to pbmcs to modify an immune response
JP7820663B1 (ja) * 2024-09-25 2026-02-26 ダイキン工業株式会社 設備管理装置、プログラム、設備管理システム

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017533702A (ja) * 2014-10-31 2017-11-16 マサチューセッツ インスティテュート オブ テクノロジー 生体分子の免疫細胞への送達
WO2019178005A2 (en) * 2018-03-12 2019-09-19 Sqz Biotechnologies Company Methods for treating hpv-associated diseases
WO2020112493A1 (en) * 2018-11-29 2020-06-04 Board Of Regents, The University Of Texas System Methods for ex vivo expansion of natural killer cells and use thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CANCER IMMUNOL IMMUNOTHER, vol. 55, JPN6025024910, 2005, pages 819 - 29, ISSN: 0005621380 *
CANCER IMMUNOL IMMUNOTHER, vol. 57, JPN6025024911, 2008, pages 1569 - 77, ISSN: 0005621381 *
FEBS LETT, vol. 348, JPN6025024909, 1994, pages 109 - 13, ISSN: 0005763308 *
PLOS ONE, vol. 7, JPN6025024912, 2012, pages 30264, ISSN: 0005621382 *
PNAS, vol. 107, JPN6025024908, 2010, pages 13824 - 9, ISSN: 0005763307 *

Also Published As

Publication number Publication date
CN116406283A (zh) 2023-07-07
WO2022051437A2 (en) 2022-03-10
KR20230079066A (ko) 2023-06-05
TW202227125A (zh) 2022-07-16
US20230263879A1 (en) 2023-08-24
EP4208192A2 (en) 2023-07-12
WO2022051437A3 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
JP7610773B2 (ja) 免疫応答を改変するためのｐｂｍｃへの生体分子の送達
JP7523203B2 (ja) 生体分子の免疫細胞への送達
Pierce et al. Targeting natural killer cells for improved immunity and control of the adaptive immune response
KR102028340B1 (ko) 항원-특이적 t 세포의 증식 방법
US9492529B2 (en) Method for priming of T cells
Matthews et al. Potent induction of antibody-secreting B cells by human dermal-derived CD14+ dendritic cells triggered by dual TLR ligation
KR20200130371A (ko) Hpv-연관 질환을 치료하는 방법
JP2021503959A (ja) がんおよび関連悪性腫瘍の治療のためのγδＴ細胞を活性化、修飾、および増殖させる方法
TW201814041A (zh) 用於病毒專一性t細胞之活化及增生的平台
Hont et al. The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease
JP2023539370A (ja) 有核細胞を使用してタンパク質に対するｈｌａ非依存的な免疫応答を刺激する方法
CN111094553A (zh) 用于癌症治疗的改良同种异体树突状细胞
JP2021516957A (ja) パラポックスウイルスベクター
AU2021273101A1 (en) SARS-CoV-2-specific T cells
US20090041792A1 (en) Dendritic cells, uses therefor, and vaccines and methods comprising the same
JP7812530B2 (ja) Ｅｂｖ複合抗原、樹状細胞ワクチンおよびその使用
AU2013262426A1 (en) Cellular vaccine and method of inducing an immune response in a subject
RU2799784C2 (ru) Способы лечения заболеваний, ассоциированных с впч
Glauß the Fusogenic VSV-NDV Platform for Oncolytic Viro-Immunotherapy by Transgene Expression of Cytokines
Davies Virus-Positive Merkel Cell Carcinoma Specific T Cells Are Robustly Generated from Healthy Donor Blood
HK40018462A (en) Improved allogeneic dendritic cells for use in cancer treatment
Kast Reversal of Human Papillomavirus-Specific T
Van Den Bosch Development of cellular immunotherapy for CMV and HIV infection using mRNA-transfected antigen-presenting cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250618

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250918

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260105